BPTH On Steady Path, Cancer Genetics On Watch, GLPG/GILD Scrap IPF Drug, REGN's Libtayo Gets FDA Nod Read on. 1. Bio-Path On A Steady Path Bio-Path Holdings Inc. (BPTH) has been granted the third U.S. patent, expanding the protection of its DNAbilize platform technology that helps to deliver DNA therapeutics directly to cancer cells. In addition, the company is expected to be issued a patent related to its lead product candidate, Prexigebersen, in combination with either a cytidine analogue, such as decitabine, or the Bcr-Abl tyrosine kinase inhibitors dasatinib and nilotinib, on February 23, 2021. Prexigebersen is in a Phase 2 study for blood cancers and Prexigebersen-A, a drug product modification of Prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors.